Tone mix
Week by week 51 weeks
Share of Zymeworks Inc.'s 172 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Feb 23, 2026 · tone -93Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year-98
- Week of Jan 19, 2026 · tone +100Zymeworks Inc. (NASDAQ:ZYME) Given Average Rating of "Buy" by Analysts+91
- Week of Sep 8, 2025 · tone +100Zymeworks Inc. (NYSE:ZYME) Receives Consensus Recommendation of "Moderate Buy" from Brokerages+88
- Week of May 4, 2026 · tone -66Zymeworks (NASDAQ:ZYME) Releases Quarterly Earnings Results, Misses Estimates By $0.49 EPS-83
- Week of May 26, 2025 · tone +99Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer+82
- Week of Sep 1, 2025 · tone -71Zymeworks Halts Development Of Cancer Drug After Trial Setback-77
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Zymeworks Inc. in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 8 | +69 |
| Last 30 sessions | 16 | +46 |
| Last 90 sessions | 39 | +44 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Wednesday, October 28, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletZymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal UpsidePositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
5 headlines, average tone +50: 3 positive, 2 neutral and 0 negative. Showing all 5.
- www.recorder.ca · 18 outletsZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026Neutral
- econotimes.com · 1 outletRoche Signs Conditional Global License Deal for Zymeworks' ZW209 ProgramPositive
- www.rttnews.com · 1 outletZymeworks Licenses Cancer Drug Candidate ZW209 To Roche In Deal Worth Up To $813 MillionPositive
- www.bioxconomy.com · 1 outletZymeworks licenses cancer therapy to Roche for up to $813mPositive
- www.finanznachrichten.de · 1 outletZymeworks Inc.: Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026Neutral
Show the table · 5 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026 | www.recorder.ca | 18 | Neutral |
| Roche Signs Conditional Global License Deal for Zymeworks' ZW209 Program | econotimes.com | 1 | Positive |
| Zymeworks Licenses Cancer Drug Candidate ZW209 To Roche In Deal Worth Up To $813 Million | www.rttnews.com | 1 | Positive |
| Zymeworks licenses cancer therapy to Roche for up to $813m | www.bioxconomy.com | 1 | Positive |
| Zymeworks Inc.: Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026 | www.finanznachrichten.de | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
2 headlines, average tone +100: 2 positive, 0 neutral and 0 negative. Showing all 2.
- www.thesudburystar.com · 4 outletsZymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3Positive
- www.finanznachrichten.de · 1 outletZymeworks Inc.: Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3Positive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3 | www.thesudburystar.com | 4 | Positive |
| Zymeworks Inc.: Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3 | www.finanznachrichten.de | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 20, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- econotimes.com · 1 outletZymeworks Names Suzanne Monahan to Lead YUPELRI Commercial StrategyNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Zymeworks Names Suzanne Monahan to Lead YUPELRI Commercial Strategy | econotimes.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 19, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.recorder.ca · 4 outletsZymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance BiopharmaNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma | www.recorder.ca | 4 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Zymeworks Inc., not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.